Antibody responses against HTLV-۱ using nasal and subcutaneous administration of recombinant vaccine loaded in PLGA nanoparticles

The mucosal and systemic immunity of HTLV-۱ fusion epitope-loaded PLGA nanoparticles (NPs) was evaluated in a mice model. For this purpose, the multi-epitope chimera including Tax, env, and gag immunodominant HTLV-۱ epitopes was encapsulated in biodegradable PLGA NPs. PLGA nanospheres produced by a double emulsion method had a size of < ۲۰۰ nm and the encapsulation efficiency of chimera antigen was ۸۵%. The release profile of radiolabeled chimera indicated that only ۱۷.۴% of chimera were released from PLGA NPs during one month. The PLGA formulations significantly elevated titers of IgG۱, IgG۲a, and sIgA antibodies relative to the other vaccines. These results revealed that the sustained release of chimera from PLGA as an efficient polymeric system elicited potent cell-mediated and mucosal immunity without inflammatory responses against HTLV-۱. Therefore, the appropriate design of vaccine formulation and immunization strategy are crucial factors to construct an efficient vaccine

کلیدواژه ها:

Recombinant vaccine ، PLGA ، Mucosal immunity ، Cellular response ، Antibody assay ، HTLV-۱.